List of Qulipta drug patents

Qulipta is owned by Abbvie Inc.

Qulipta contains Atogepant.

Qulipta has a total of 4 drug patents out of which 0 drug patents have expired.

Qulipta was authorised for market use on 28 September, 2021.

Qulipta is available in tablet;oral dosage forms.

Qulipta can be used as preventive treatment of episodic migraine in adults.

Drug patent challenges can be filed against Qulipta from September, 2025.

The generics of Qulipta are possible to be released after 30 January, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9499545 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US8754096 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

US9850246 ABBVIE INC Process for making CGRP receptor antagonists
Mar, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836 ABBVIE INC Tablet formulation for CGRP active compounds
Jan, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in